Welcome to our dedicated page for Scpharmaceutical SEC filings (Ticker: SCPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial data, FDA correspondence, and cash-runway projections make scPharmaceuticals’ SEC filings anything but light reading. Finding when officers file scPharmaceuticals insider trading Form 4 transactions or parsing risk disclosures around FUROSCIX often means wading through hundreds of pages.
Stock Titan solves that. Our AI translates dense biotech language into clear takeaways, flagging each scPharmaceuticals quarterly earnings report 10-Q filing within minutes of hitting EDGAR. Whether you need scPharmaceuticals Form 4 insider transactions real-time alerts, a one-page brief on liquidity ratios, or guidance for understanding scPharmaceuticals SEC documents with AI, we surface the essentials so you can focus on decisions, not document mining.
Here’s what you’ll uncover:
- Trial milestones and FDA updates via scPharmaceuticals 8-K material events explained
- Segment spend, revenue outlook, and pipeline costs in each scPharmaceuticals earnings report filing analysis
- Executive pay details from the scPharmaceuticals proxy statement executive compensation
- Real-time alerts on scPharmaceuticals executive stock transactions Form 4
- Full risk-factor commentary in the scPharmaceuticals annual report 10-K simplified
Every filing—10-K, 10-Q, 8-K, Form 4, DEF 14A—is indexed seconds after release, summarized by AI, and paired with expert context. Compare quarter-over-quarter R&D spend, monitor insider sentiment before material news, or track manufacturing agreements without digging through PDFs. Complex biotech disclosures, clarified.
Luther King Capital Management Corp. (LKCM) and its founder, J. Luther King, Jr., have filed Amendment No. 6 to Schedule 13G for scPharmaceuticals Inc. (SCPH) dated 30 Jun 2025. The filing discloses continued beneficial ownership above the 5 % threshold:
- LKCM reports 3,541,170 common shares with sole voting and dispositive power, representing 6.7 % of SCPH’s outstanding stock.
- J. Luther King, Jr. individually reports 3,669,170 common shares (sole voting/dispositive power) for a 7.0 % stake.
The amendment confirms that the shares are held in the ordinary course of business and not for the purpose of influencing control of the issuer. Both reporting persons classify as an “Investment Adviser” (LKCM) and “Individual” (King) under Rule 13d-1(b). No joint filing or group status is claimed, and there are no shared voting or dispositive powers.
Implications for investors: 1) LKCM remains one of SCPH’s larger institutional holders, potentially signaling confidence in the company’s prospects. 2) Because the ownership level is stable at ~7 %, the amendment itself does not suggest an imminent change in strategic direction or control. 3) Any future movement above or below the 5 % threshold would trigger additional filings, providing transparency on LKCM’s trading activity.
FAQ
What is the current stock price of Scpharmaceutical (SCPH)?
What is the market cap of Scpharmaceutical (SCPH)?
What is the core mission of scPharmaceuticals?
What differentiates FUROSCIX from traditional therapies?
How does scPharmaceuticals generate revenue?
In which therapeutic areas is scPharmaceuticals focused?
What role does technology play in scPharmaceuticals' operations?
How does scPharmaceuticals position itself in a competitive market?
What are some key aspects of the company's clinical development strategy?
How does scPharmaceuticals contribute to reducing healthcare costs?
